Drospirenone

Drospirenone Structure
Drospirenone structure
Common Name Drospirenone
CAS Number 67392-87-4 Molecular Weight 366.493
Density 1.3±0.1 g/cm3 Boiling Point 552.2±50.0 °C at 760 mmHg
Molecular Formula C24H30O3 Melting Point 196-200ºC
MSDS Chinese USA Flash Point 241.6±30.2 °C
Symbol GHS08
GHS08
Signal Word Danger

Postural tachycardia syndrome (POTS).

Circulation 127(23) , 2336-42, (2013)

Sexual function, mood and menopause symptoms in Lithuanian postmenopausal women.

Climacteric 16(1) , 185-93, (2013)

To assess sexual function in a clinical sample of Lithuanian postmenopausal women and identify the most important determinants of sexual function, including the use of hormone replacement therapy (HT), emotional status and menopausal symptoms.Three hundred po...

Liquid chromatography with diode array detection and multivariate curve resolution for the selective and sensitive quantification of estrogens in natural waters.

Anal. Chim. Acta 835 , 19-28, (2014)

Following the green analytical chemistry principles, an efficient strategy involving second-order data provided by liquid chromatography (LC) with diode array detection (DAD) was applied for the simultaneous determination of estriol, 17β-estradiol, 17α-ethiny...

In search of the best combined oral contraceptive for treatment of polycystic ovary syndrome.

Fertil. Steril. 98(4) , 825-6, (2012)

Comparative study of the therapeutic effects of oral contraceptive pills containing desogestrel, cyproterone acetate, and drospirenone in patients with polycystic ovary syndrome.

Fertil. Steril. 98(4) , 1053-9, (2012)

To compare the effects of oral contraceptive pills containing desogestrel, cyproterone acetate, and drospirenone, in polycystic ovary syndrome (PCOS), after 6 and 12 months of therapy.Double-blind randomized controlled trial.Gynecologic clinic of the first au...

Comparison of two oral contraceptive forms containing cyproterone acetate and drospirenone in the treatment of patients with polycystic ovary syndrome: a randomized clinical trial.

Arch. Gynecol. Obstet. 290(2) , 321-8, (2014)

To compare the effects of combined oral contraceptives (OCs) containing cyproterone acetate and drospirenone in the treatment of polycystic ovary syndrome (PCOS).Fifty-two patients with PCOS were randomized in two groups: group A (n = 26) received 0.035 mg et...

The “newer” progestogens and postmenopausal hormone therapy (HRT)

J. Steroid Biochem. Mol. Biol. 142 , 48-51, (2014)

• The “newer” progestogens have a high bioavailability. • The “newer” progestogens have a sufficient progestogenic effect. • The “newer” progestogens do not cause undue side effects. • The “newer” progestogens do not jeopardize lipid- and carbohydrate metabol...

Low-dose estrogen and drospirenone combination: effects on metabolism and endothelial function in postmenopausal women with metabolic syndrome.

Clin. Exp. Obstet. Gynecol. 40(2) , 233-5, (2013)

Metabolic syndrome and endothelial dysfunction play a relevant role in the cardiovascular risk in post-menopause. The aim of the study was to assess the effects of a low-dose hemihydrate estradiol and drospirenone combination on cardiovascular risk parameters...

Dual suppression with oral contraceptive pills in GnRH antagonist cycles for patients with polycystic ovary syndrome undergoing intracytoplasmic sperm injection.

Eur. J. Obstet. Gynecol. Reprod. Biol. 183 , 137-40, (2014)

To evaluate the effects of a gonadotropin-releasing hormone (GnRH) antagonist protocol, with or without oral contraceptive pill (OCP) pretreatment, in patients with polycystic ovary syndrome (PCOS) undergoing intracytoplasmic sperm injection (ICSI).In this re...

Progestin-dependent effect of oral contraceptives on plasma aldosterone/renin ratio.

Clin. Biochem. 45(16-17) , 1516-8, (2012)

Estrogens in oral contraceptives (OC) may influence plasma aldosterone/plasma renin activity (ALD/PRA) and plasma aldosterone/plasma renin concentration (ALD/DRC) ratios, but the effect of progestins on these ratios has not been sufficiently studied so far.PR...